PHARMANIAGA |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.335 MYR | 0.00% |
|
-1.47% | -12.99% |
| Apr. 19 | China's drugmakers can't sell mRNA shots but haven't quit yet | RE |
| Mar. 27 | Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee | CI |
| Sales 2023 | 3.4B 713M | Sales 2024 * | 3.34B 699M | Capitalization | 483M 101M |
|---|---|---|---|---|---|
| Net income 2023 | -77M -16.13M | Net income 2024 * | 45M 9.43M | EV / Sales 2023 | 0.16 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 0.14 x |
| P/E ratio 2023 |
-6.8
x | P/E ratio 2024 * |
10.8
x | Employees | 3,778 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 41.76% |
More Fundamentals
* Assessed data
More news
| 1 week | -1.47% | ||
| Current month | -5.63% | ||
| 1 month | -2.90% | ||
| 3 months | -11.84% | ||
| 6 months | -18.29% | ||
| Current year | -12.99% |
1 week
0.33
0.34
1 month
0.330.37
Current year
0.330.44
1 year
0.300.51
3 years
0.221.45
5 years
0.181.45
10 years
0.181.51
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 57 | 01-04-30 | |
| Chief Tech/Sci/R&D Officer | 52 | 22-12-31 | |
| Chief Tech/Sci/R&D Officer | 56 | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 55 | 22-11-29 | |
| Corporate Officer/Principal | 52 | 20-08-02 | |
| Director/Board Member | 49 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.335 | 0.00% | 514 400 |
| 24-04-24 | 0.335 | 0.00% | 426,500 |
| 24-04-23 | 0.335 | 0.00% | 281,100 |
| 24-04-22 | 0.335 | 0.00% | 339,400 |
| 24-04-19 | 0.335 | 0.00% | 784,800 |
End-of-day quote BURSA MALAYSIA, April 23, 2024
More quotes
Pharmaniaga Berhad is an investment holding company. The Company is principally engaged in the research and development, manufacturing of generic drugs and medical devices, logistics and distribution, sales, and marketing, as well as community pharmacy. The Company operates through three segments: Logistics and distribution, Manufacturing, and Indonesia. The Logistics and distribution is engaged in the distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia. The Manufacturing segment is engaged in the manufacturing of pharmaceutical products in Malaysia. Indonesia segment is engaged in the manufacturing and distribution of pharmaceutical and medical products in Indonesia. The Companyâs subsidiaries include Idaman Pharma Manufacturing Sdn. Bhd., Pharmaniaga Manufacturing Berhad, Pharmaniaga LifeScience Sdn. Bhd., Pharmaniaga Logistics Sdn. Bhd., and Pharmaniaga Marketing Sdn. Bhd.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.335
MYR
Average target price
0.31
MYR
Spread / Average Target
-7.46%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.99% | 101M | |
| +15.65% | 70.36B | |
| +2.72% | 25.18B | |
| +6.36% | 8.61B | |
| +6.10% | 8.14B | |
| -21.85% | 7.83B | |
| +0.18% | 4.56B | |
| +17.40% | 4.32B | |
| -0.14% | 4.06B | |
| -2.61% | 3.87B |
- Stock Market
- Equities
- PHARMA Stock
